Employees: 01 (2023.0)Legal category: 5485Size: PMECreation date: 2018-12-28 (7 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: BONDUES (59910), Nord
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE LEPERS - MAURICE : revenue, balance sheet and financial ratios
SELARL PHARMACIE LEPERS - MAURICE is a French company
founded 7 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in BONDUES (59910),
this company of category PME
shows in 2023 a revenue of 1.3 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE LEPERS - MAURICE (SIREN 844933309)
Indicator
2025
2024
2023
2022
2021
2020
Revenue
N/C
N/C
1 277 687 €
N/C
N/C
N/C
Net income
22 054 €
-18 108 €
37 878 €
159 531 €
62 683 €
907 €
EBITDA
N/C
N/C
58 206 €
N/C
N/C
N/C
Net margin
N/C
N/C
3.0%
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE LEPERS - MAURICE generates positive net income of 22 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2025: 907 € -> 22 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
22 054 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 62%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 49%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
62.241%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
48.736%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE LEPERS - MAURICE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2020
2021
2022
2023
2024
2025
Debt ratio
901.678
385.662
150.552
93.251
81.212
62.241
Financial autonomy
8.018
16.693
29.342
40.916
42.555
48.736
Repayment capacity
None
None
None
5.674
None
None
Cash flow / Revenue
None%
None%
None%
4.0%
None%
None%
Sector positioning
Debt ratio
62.242025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average
In 2025, the debt ratio of SELARL PHARMACIE LEPERS -... (62.24) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
48.74%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average
In 2025, the financial autonomy of SELARL PHARMACIE LEPERS -... (48.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
5.67 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of SELARL PHARMACIE LEPERS -... (5.67) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 203.51. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
203.511
Liquidity indicators evolution SELARL PHARMACIE LEPERS - MAURICE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2020
2021
2022
2023
2024
2025
Liquidity ratio
237.996
246.134
211.406
225.283
191.089
203.511
Interest coverage
None
None
None
6.317
None
None
Sector positioning
Liquidity ratio
203.512025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good
In 2025, the liquidity ratio of SELARL PHARMACIE LEPERS -... (203.51) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
6.32x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of SELARL PHARMACIE LEPERS -... (6.3x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE LEPERS - MAURICE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
205 746 €
0 €
0 €
Inventory turnover (days)
0
0
0
28
0
0
Customer payment term (days)
0
0
0
6
0
0
Supplier payment term (days)
0
0
0
43
0
0
Positioning of SELARL PHARMACIE LEPERS - MAURICE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE LEPERS - MAURICE is estimated at
350 330 €
(range 237 735€ - 549 716€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
237k€350k€549k€
350 330 €Range: 237 735€ - 549 716€
NAF 5 année 2025
Valuation method used
Net Income Multiple
22 054 €
×
15.9x
=350 330 €
Range: 237 736€ - 549 717€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE LEPERS - MAURICE with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE LEPERS - MAURICE
What is the revenue of SELARL PHARMACIE LEPERS - MAURICE ?
The revenue of SELARL PHARMACIE LEPERS - MAURICE in 2023 is 1.3 M€.
Is SELARL PHARMACIE LEPERS - MAURICE profitable?
Yes, SELARL PHARMACIE LEPERS - MAURICE generated a net profit of 22 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE LEPERS - MAURICE ?
The headquarters of SELARL PHARMACIE LEPERS - MAURICE is located in BONDUES (59910), in the department Nord.
Where to find the tax return of SELARL PHARMACIE LEPERS - MAURICE ?
The tax return of SELARL PHARMACIE LEPERS - MAURICE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE LEPERS - MAURICE operate?
SELARL PHARMACIE LEPERS - MAURICE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart